Latest News and Press Releases

PRINCETON, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering by certain selling...

PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2021. ...

PRINCETON, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that James E. Cashman III, a current Board member, will be...

PRINCETON, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William F. Feehery, Chief Executive Officer, and Andrew...

PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has awarded a...

PRINCETON, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100...

PRINCETON, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of...

新泽西州普林斯顿, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Certara 为全球生物模拟领域的领军企业，今日宣布推出一款全新的监管 SaaS 产品——Synchrogenix™ Writer。该产品可加快患者叙述的撰写和审查速度。患者叙述描述了不良事件或药物不良反应，对于整个临床阶段的每个治疗领域的临床研究报告都至关重要。 ...

PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of...

新泽西州普林斯顿, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Certara, Inc.（纳斯达克代码：CERT）为全球生物模拟领域的领军企业，今日宣布完成此前公布的 Pinnacle 21 收购交易，Pinnacle 21 为面向临床数据拟合、监管合规和审批准备的 SaaS 解决方案领先提供商。该交易完成后，Pinnacle 21 的股权持有人获得了约 2.5...